Cite
HARVARD Citation
Wise-Draper, T. et al. (n.d.). 809 Phase 2 trial of neoadjuvant and adjuvant PD-1 checkpoint blockade in local-regionally advanced, resectable HNSCC indicates pathological response is associated with high disease-free survival. Journal for immunotherapy of cancer. pp. A859-A860. [Online].